Corton Capital’s Cytek Biosciences CTKB Stock Holding History

Corton Capital’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,129	Closed	-$64.7K	–	353
2025 Q1	$64.7K	Buy	+16,129	New	+$83.6K	0.21%	154

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Corton Capital's CTKB Position: Q2 2025 in Review

Corton Capital sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 16,129 shares — an estimated $64.7K sold.

Corton Capital first reported a position in CTKB in Q1 2025 and held it in 1 quarter. The position peaked at $64.7K in Q1 2025. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

Corton Capital reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
Corton Capital sold 16,129 Cytek Biosciences shares in Q2 2025, an estimated $64.7K.
Corton Capital first reported a position in Cytek Biosciences in Q1 2025 and held it in 1 quarter.
Corton Capital's Cytek Biosciences position peaked at $64.7K in Q1 2025.
158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.